Mechanism of action

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

Retrieved on: 
Monday, January 22, 2024
Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

Key Points: 
  • However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
  • In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
  • Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
  • As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Safety, SAN, D, Carcinoma, Sarcoma, Investment, PD, Cohort study, Patient, Research, Chordoma, Lung cancer, Conference, KRON, Ovarian cancer, Cancer, Mechanism of action, AACR, Genentech, Life insurance, Rare-earth element, Pharmaceutical industry

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2023 financial results.

Key Points: 
  • $198.4 million in cash, cash equivalents and investments as of September 30, 2023
    SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2023 financial results.
  • “This quarter, we made great strides in advancing our clinical programs as well as our discovery projects and Genentech collaboration,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • Kronos Bio expects that these efforts, which include a 19% reduction in force, will extend its cash runway into 2026.
  • Net Loss: Net loss for the third quarter of 2023 was $31.4 million, or $0.54 per share, including non-cash stock-based compensation expense of $6.3 million.

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Retrieved on: 
Thursday, November 2, 2023
KRON, Genentech, Cancer, AACR, Safety, Mechanism of action, Patient, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and contain costs in light of the positive preliminary safety and efficacy clinical data from its Phase 1/2 study of KB-0742. This plan positions the company to maximize the potential of KB-0742 while continuing to advance the development of lanraplenib, currently in the dose escalation portion of a Phase 1b/2 study. The company will also focus its discovery efforts on maturing projects and its Genentech collaboration activities. Kronos Bio expects that these restructuring efforts, which include a 19% reduction in force, will extend its cash runway into 2026.

Key Points: 
  • This plan positions the company to maximize the potential of KB-0742 while continuing to advance the development of lanraplenib, currently in the dose escalation portion of a Phase 1b/2 study.
  • The company will also focus its discovery efforts on maturing projects and its Genentech collaboration activities.
  • Kronos Bio expects that these restructuring efforts, which include a 19% reduction in force, will extend its cash runway into 2026.
  • At the recent AACR-NCI-EORTC meeting, we shared positive preliminary efficacy and safety data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study.

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Mechanism of action, Trial of the century, AACR, Vomiting, Lung cancer, Drug, Conference, Doctor of Philosophy, Carcinoma, CDK9, Nausea, KRON, Kronos, Learning, Case Western Reserve University, Ewing sarcoma, Washington University School of Medicine, Neoplasm, Sarcoma, Safety, Cancer, Patient, Neutropenia, SAN, Rhabdomyosarcoma, Fatigue, Pharmaceutical industry, Medicine

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting in Dublin, Ireland. Today’s presentation by Dr. Van Tine of Washington University School of Medicine includes clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Massachusetts in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.

Key Points: 
  • Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.
  • Today, I shared a case study on one of my sarcoma patients who exhausted all standard therapies as well as multiple experimental treatments.
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • To learn more about the preliminary positive KB-0742 data presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass.

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Retrieved on: 
Friday, October 13, 2023
Cancer, Lung cancer, Sarcoma, City of Hope National Medical Center, Drug, M.D, Plasma, Vomiting, Breast, AACR, PIN, CDK9, Safety, Half-life, Nausea, Therapy, RECIST, City, Neutropenia, Fatigue, KRON, Chordoma, Mechanism of action, SAN, Patient, Lung, Q&A, Neoplasm, PR, Cmax, Conference, Myxoid liposarcoma, Pharmaceutical industry

The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).

Key Points: 
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • KB-0742 also demonstrated dose proportional exposure and target engagement and a 24-hour plasma half-life, enabling intermittent dosing.
  • Because the maximum tolerated dose has not yet been identified, enrollment in the dose escalation portion continues and dosing of patients at the 80 mg dose level is underway.
  • “These positive preliminary efficacy and safety data underscore the promise of KB-0742 to treat patients with transcriptionally addicted tumors.

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Retrieved on: 
Tuesday, August 1, 2023
Gland, Cell death, SARS-CoV-2, Glucocorticoid, Pancreas, Bone marrow, Toxicity, Research, Harvard Medical School, Massachusetts General Hospital, Patient, IgG4-related disease, Risk, Edward, Mass, Hospital, MPH, Mechanism of action, Lancet, Nursing, Pharmaceutical industry, Wood drying, Medicine, Safety, MD

WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, announces The Lancet Rheumatology has published findings from a Phase 2 study evaluating obexelimab for the treatment of patients with IgG4-Related Disease (IgG4-RD). Based on the results of this study, a Phase 3 study in patients with IgG4-RD is ongoing to further investigate the efficacy and safety of obexelimab administered as a subcutaneous injection.

Key Points: 
  • IgG4-RD is a chronic, immune-mediated fibro-inflammatory disease that can affect multiple organs including the major salivary glands, orbits, lacrimal glands, pancreas, biliary tree, lungs, kidneys, and retroperitoneum.
  • Despite its increasing recognition, there remains a need for further research and effective therapeutic options for individuals living with this debilitating disease.
  • Across the world, the use of glucocorticoids is widely considered to be the standard of care for treating IgG4-RD.
  • “Our team is honored to have our research recognized by The Lancet Rheumatology, and we are immensely grateful to the patients who participated in this groundbreaking study.”

Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal

Retrieved on: 
Wednesday, March 29, 2023
Vaccine, NMR, Chills, Infection, Covid-19 hospital, COVID-19, Clinical trial, Viral, Sensation, Drug design, Science, Lectin, Membrane, Pandemic, Patient, Article, Immune system, Carbohydrate, Escape Room, Viral load, Mechanism of action, Virus, PCR, COVID19, Disease, Pharmaceutical industry

BOSTON, MASSACHUSETTS, March 29, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).

Key Points: 
  • During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered.
  • The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).
  • Our analysis also revealed an 82% responders rate by day 3, which was statistically significant (p-value = .001).
  • The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Saturday, December 10, 2022
Investigational New Drug, NKT, MCRPC, Clinical trial, PD, Cytokine release syndrome, Poster, Safety, CLL, Cancer, Multiple myeloma, CD1D, Pharmacokinetics, Toxic shock syndrome, Exposition, Trial of the century, ASH, Mechanism of action, Monoclonal antibody, AML, CRS, Acute myeloid leukemia, LAVA, Growth, Chronic lymphocytic leukemia, Research, Society, PK, Therapy, MM, COVID-19, Patient, Pharmaceutical industry, Vaccine, EU

The presentation includes initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts.

Key Points: 
  • The presentation includes initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts.
  • “The LAVA Therapeutics team is committed to transforming treatment for people living with cancer,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.
  • A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling ( NCT05369000 ).
  • LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Indegene acquires CultHealth, a full-service, healthcare marketing agency to elevate brand experience

Retrieved on: 
Wednesday, October 19, 2022
Physician, Health, Medicine, Culture, MOA, Efficiency, CRM, DTC, Patient, Medication, NEW, Mechanism of action, Drug discovery, Acquisition, Marketing, TV, CEO, Social media, Diabetes, Seyfarth Shaw, GLOBE, LLP, Solution, HCPS, Pharmaceutical industry, Management, Medical device, Indegene

CultHealth is a U.S.-based, full-service, healthcare marketing agency with significant experience in medical strategy, creative and omnichannel planning services.

Key Points: 
  • CultHealth is a U.S.-based, full-service, healthcare marketing agency with significant experience in medical strategy, creative and omnichannel planning services.
  • With CultHealth, our life sciences clients benefit from partnering with a single service provider, all the way from brand strategy through commercialization.
  • We believe that together we can build outstanding brand experiences, improve the effectiveness and efficiency of life sciences commercialization, and enable future ready healthcare.
  • To learn more, please visit www.indegene.com
    CultHealth is a full-service advertising and marketing agency focused on the unique needs of healthcare marketers.

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Friday, October 7, 2022
LinkedIn, LAVA, Therapy, Growth, YouTube, Research, Twitter, Immunotherapy, Nasdaq, Society for Immunotherapy of Cancer, Company, Society, Mechanism of action, GLOBE, Forward-looking statement, Monoclonal antibody, COVID-19, Poster, Pharmaceutical industry, Vaccine

The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V9V2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.

Key Points: 
  • The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V9V2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens.
  • For more information, please visit www.lavatherapeutics.com ,and follow uson LinkedIn , Twitter and YouTube .
  • This press release contains forward-looking statements, including with respect to the companys anticipated growth and clinical development plans, including the timing of clinical trials.
  • LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.